Statins in Patients With Type 2 Diabetes Mellitus and Previous History of Acute Coronary Syndrome
Status:
Completed
Trial end date:
2021-01-31
Target enrollment:
Participant gender:
Summary
The purpose of this study was to compare the efficacy and safety of high dose atorvastatin
(40 mg) versus high dose rosuvastatin (20 mg) in Egyptian type II diabetic patients with
previous acute coronary syndrome history. This open-labeled prospective, randomized clinical
trial compared once daily atorvastatin 40mg (Ator®) versus once daily rosuvastatin 20mg
(Crestor®). The primary outcome was the 50% reduction in low-density lipoprotein cholesterol
levels at 12 weeks. The secondary outcome was the achievement of low-density lipoprotein
cholesterol level < 55 mg/dl.